featured
Hematology Practice Implications: New Large Cell Lymphoma Research
Interview by
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Neelapu SS, Locke FL, Bartlett NL, et al. Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 7559.
- Kochenderfer J, Somerville R, Lu T, et al. Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract LBA3010.
Disclosure statements are available on the authors' profiles: